- Home
- PDEX vs CGEN Comparison
PDEX vs CGEN Comparison
Compare PDEX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- CGEN
- Stock Information
- Founded
- PDEX 1978
- CGEN 1993
- Country
- PDEX United States
- CGEN Israel
- Employees
- PDEX N/A
- CGEN N/A
- Industry
- PDEX Medical/Dental Instruments
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDEX Health Care
- CGEN Health Care
- Exchange
- PDEX Nasdaq
- CGEN Nasdaq
- Market Cap
- PDEX 152.3M
- CGEN 125.3M
- IPO Year
- PDEX N/A
- CGEN 2000
- Fundamental
- Price
- PDEX $33.25
- CGEN $1.91
- Analyst Decision
- PDEX Strong Buy
- CGEN
- Analyst Count
- PDEX 1
- CGEN 0
- Target Price
- PDEX $56.00
- CGEN N/A
- AVG Volume (30 Days)
- PDEX 33.2K
- CGEN 389.6K
- Earning Date
- PDEX 10-30-2025
- CGEN 11-11-2025
- Dividend Yield
- PDEX N/A
- CGEN N/A
- EPS Growth
- PDEX 345.00
- CGEN N/A
- EPS
- PDEX 2.67
- CGEN N/A
- Revenue
- PDEX $66,593,000.00
- CGEN $22,144,000.00
- Revenue This Year
- PDEX $7.22
- CGEN N/A
- Revenue Next Year
- PDEX N/A
- CGEN $208.08
- P/E Ratio
- PDEX $13.13
- CGEN N/A
- Revenue Growth
- PDEX 23.68
- CGEN N/A
- 52 Week Low
- PDEX $26.28
- CGEN $1.13
- 52 Week High
- PDEX $70.26
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- PDEX 38.70
- CGEN 72.60
- Support Level
- PDEX $32.17
- CGEN $1.30
- Resistance Level
- PDEX $35.50
- CGEN $1.82
- Average True Range (ATR)
- PDEX 1.38
- CGEN 0.12
- MACD
- PDEX 0.41
- CGEN 0.05
- Stochastic Oscillator
- PDEX 31.56
- CGEN 87.77
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.